SS-3091

SS-3091 (20-100 μM) directly binds to purified KRAS^G12D protein, increasing its thermal stability^[1].
SS-3091 potently inhibits the proliferation of KRAS^G12C 4B (IC₅₀ = 27.70 nM), KRAS^G12C 4A (IC₅₀ = 144.05 nM), KRAS^G12D 4B (IC₅₀ = 238.15 nM), and KRAS^G12D 4A (IC₅₀ = 575.00 nM) transformed Ba/F3 cells, with weaker activity against wild-type Ba/F3 cells (IC₅₀ = 2374.00 nM)^[1].
SS-3091 potently inhibits proliferation of KRAS^G12D, KRAS^G12C, KRAS^G12V, KRAS^G12S, and KRAS^G12A mutant cancer cell lines (IC₅₀ values ranging from 39.23 nM to 1253.60 nM), with weaker or no activity against non-KRAS-driven cancer cell lines^[1].
SS-3091 (50-300 nM) dose-dependently suppresses colony formation in PANC1, MIA-PaCa2, SW620, and A549 KRas^G12 mutant cancer cell lines^[1].
SS-3091 (0-10 μM) dose-dependently inhibits KRas downstream signaling (phosphorylation of S6K, Akt, and ERK) in ASPC1, MIA-PaCa2, SW620, and A549 KRas^G12 mutant cancer cell lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.